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Background: Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation
punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with
corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed
differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial
epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists.
Methods: Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15).
TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was measured in cell cultures after TLR3
stimulation with poly I:C 10 μg/mL.
Results: We found that TLR3 expression was increased by 1.95 fold (protein) and 2.5 fold (mRNA) in lung tissues
from smokers with COPD and inversely correlated with lung function. The TLR3 agonist poly I:C 10 μg/mL increased
the IL-8 release in HBECs that was poorly inhibited by dexamethasone in smokers (24.5%) and smokers with COPD
(21.6%). In contrast, roflumilast showed similar inhibitory effects on IL-8 release in healthy (58.8%), smokers (56.6%) and
smokers with COPD (50.5%). The combination of roflumilast N-oxide and dexamethasone showed additive inhibitory
effects. Mechanistically, roflumilast N-oxide when combined with dexamethasone increased the expression of MKP1,
and enhanced the inhibitory effects on phospho-p38, AP1 and NFκB activities which may explain the additive
anti-inflammatory effects.
Conclusions: Altogether, our data provide in vitro evidence for a possible clinical utility to add roflumilast on top
of inhaled corticosteroid in COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by irreversible airflow obstruction, inflamma-
tion, and a progressive decline in lung function [1]. The
primary cause of COPD is chronic exposure to cigarette
smoke, which leads to airway inflammation and remod-
eling, thus increasing airflow limitation.* Correspondence: xmilara@hotmail.com
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unless otherwise stated.The current first-line maintenance treatment for COPD
involves the use of bronchodilators, including long-acting
muscarinic antagonists (LAMAs) and long-acting beta
agonists (LABAs), in combination with inhaled corticoste-
roids in those patients with severe COPD who are at risk
of exacerbations. However, in contrast to other inflam-
matory diseases, corticosteroids are less effective in im-
proving lung function and have little or no effect on
controlling the underlying chronic inflammation in COPD
patients [2]. The poor anti-inflammatory properties of
corticosteroids in COPD have increased the development
of other anti-inflammatory drugs. This is the case of roflu-
milast, the first phosphodiesterase–4 (PDE4) inhibitorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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duce the risk of COPD exacerbations associated with
chronic bronchitis in patients with severe COPD and a his-
tory of exacerbations. In preclinical models, roflumilast and
its active metabolite, roflumilast N-oxide, have been shown
to inhibit a broad spectrum of inflammatory cytokines and
reactive oxygen species (ROS) in different inflammatory
and non-inflammatory cells relevant to COPD [3].
Exacerbations of COPD are the major cause of morbid-
ity and mortality and are associated with accelerated de-
cline in lung function and progression of the disease [4].
Respiratory RNA virus infections such as human rhino-
virus (HRV), respiratory syncytial virus (RSV) and influ-
enza virus are common causes of exacerbations of COPD
[4]. In this regard, HRV-induced lung inflammation
has been recently shown to be corticosteroid resistant
[5,6]. Furthermore, neutrophilic inflammation in chronic
cigarette smoking mice exacerbated with influenza virus
infection was resistant to dexamethasone [7]. Similarly,
the toll like receptor 3 (TLR3) agonist, poly I:C, induced a
corticosteroid resistant neutrophil airway inflammation in
mice [8]. Current data suggests that roflumilast has anti-
inflammatory effects on RSV-infected bronchial epithelial
cells [9] and reverses corticosteroid resistance in neutro-
phils from COPD patients in vitro [10].
Viral exacerbations in patients with COPD are consid-
ered to be caused by inflammatory responses that over-
whelm the protective anti-inflammatory defenses [4]. In
fact, viral exacerbations increased neutrophil counts in
the bronchial walls and in bronchoalveolar lavage fluid
from COPD patients mainly through the release of neu-
trophil chemoattractant inflammatory cytokines IL-8 or
LTB4 by infected airway epithelial cells [11-14].
The double-stranded (ds) and single-stranded (ss)
RNA generated during RNA virus infection activates
TLR3 and TLR7/8, respectively, which enhance inflam-
matory and anti-viral responses as part of the host in-
nate immune defense [15]. The expression of TLR3 has
been detected in immune cells such as macrophages,
natural killer cells, CD8+ T cells, and dendritic cells, and
non-immune cells such as airway smooth muscle cells,
airway epithelial cells, and endothelial cells [16-19]. The
expression of TLR7/8 was first detected on dendritic
cells and later in leukocytes, lymphocytes, endothelial
and airway epithelial cells [20]. Despite the key role of
viral exacerbations on COPD progression, the expression
levels and distribution pattern of TLR3 and TLR7/8 in
inflammatory cells and lung tissue of COPD patients are
not sufficiently characterized and the information cur-
rently available is contradictory [17,19].
The purpose of the current study was to characterize
the expression and distribution of TLR3, TLR7, and TLR8
in lung tissue from non-smokers, smokers and smokers
with COPD and to analyze the differential effects ofroflumilast N-oxide versus corticosteroids and their poten-
tial additive or synergistic anti-inflammatory effect in
bronchial epithelial cells stimulated with TLR3/7/8 ago-
nists. Results from this study may be of potential value to
understanding the clinical benefits of combining roflumi-
last and corticosteroids for COPD treatment [21].
Methods
Patients
A total of 15 non-smoking controls, 12 current smokers
without COPD, and 15 current smokers with COPD
were included in the study. COPD patients were diag-
nosed according to the GOLD guidelines [22]. All lung
tissues studied were taken from lung explants of non-
smoking subjects in the transplant program and from
uninvolved lung tissue from smokers without COPD or
with COPD during lobectomy/wedge resection for ma-
lignant lesions in the Thoracic Surgery and Respiratory
Unit, University General Hospital Consortium, Valencia,
Spain, between 2010 and 2014. Samples of distal lung,
located as far as possible from the tumor, were chosen
for the study. All pulmonary function tests were per-
formed within 3 months before surgery or taken from
the clinical history. Clinical data from all patients (see
Table 1) were examined for possible co-morbidity. Inclu-
sion criteria comprised either non-smokers or current
smokers with or without COPD who were free of symp-
toms of upper respiratory tract infection and were not re-
ceiving antibiotics perioperatively. After selection based on
lung function, all lung tissue samples chosen for the study
were checked histologically using the following exclusion
criteria: (1) presence of tumor, (2) presence of post stenotic
pneumonia, and (3) fibrosis of lung parenchyma. The study
protocol was approved by the local research and independ-
ent ethics committee of the University General Hospital of
Valencia. Informed written consent was obtained from
each participant or their legal representative.
Isolation of primary bronchial epithelial cells and cell culture
Human bronchial epithelial cells (HBECs) from small
bronchi were isolated as previously outlined [23]. Small
pieces of human bronchi (0.5–1 mm internal diameter)
were excised from microscopically normal lung areas,
carefully dissected from lung parenchyma and plated on
collagen-coated culture dishes (10 μg/cm2 rat type I col-
lagen; Sigma) in bronchial epithelial growth medium
(BEGM), comprising bronchial epithelial basal medium
(BEBM) supplemented with bovine pituitary extract
(52 μg/ml, hydrocortisone 0.5 μg/ml), human recombin-
ant epidermal growth factor ([EGF] 25 ng/ml), epineph-
rine (0.5 μg/ml), transferrin (10 μg/ml), insulin (5 μg/ml),
retinoic acid (50 nM), triiodo-L-thyronine (6.5 ng/ml),
gentamycin (40 μg/ml), amphotericin B (50 ng/ml), and
bovine serum albumin (1.5 μg/ml). Small bronchi were
Table 1 Clinical characteristics of patients
Non-smokers (n = 15) Smokers (n = 12) Smokers with COPD (n = 15)
Sex (Female/Male) 7/8 3/9 3/12
Age (years) 60 [50–72] 60 [47–68] 55 [49–60]
Tobacco consumption, pack-year 0 40 [20–56]* 55 [34–83]*
FEV1, % predicted 92 [76–96] 87 [83–97] 73 [53–79]‡
FVC, % predicted 97 [72–107] 90 [86–99] 96 [84–114]
FEV1/FVC 78 [75–84] 80 [77–83] 61 [55–67]‡
PaO2, mmHg 94 [89–99] 85 [81–90]
† 80 [78–83]‡
PaCO2 mmHg 41 [34–47] 44 [37–48] 47 [42–54]
†
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; Pack-yr = 1 year smoking 20 cigarettes-day;
PaO2: oxygen tension in arterial blood; PaCO2: carbon dioxide tension in arterial blood; Data are the median [interquartile range]. * P < 0.05 compared with nonsmokers.
†P < 0.05 compared with nonsmokers and smokers without COPD. ‡ P < 0.05 compared with nonsmokers and smokers without COPD.
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culture plate. After a period of ~1–2 weeks, bronchial
epithelial cells were observed around the bronchi. After
trypsinization (passage 1), cells were cultured accord-
ingly for different experiments. All the experiments per-
formed in this study with primary HBEC were done on
monolayer cultures. The identity of the monolayer as
bronchial epithelial cells was confirmed using morpho-
logical criteria and immunofluorescence for cytokeratin
5 (KRT5) as well as later use of in vitro differentiation
in air-liquid interface as pseudo-stratified bronchial epi-
thelium with basal cells, ciliated cells, columnar, and
goblet cells (data not shown). Cell viability was assessed by
vital trypan blue exclusion analysis using the Countness®
automated cell counter (Life Technologies, Madrid, Spain).
Cell viability was >98% in all cell cultures.
The bronchial epithelial BEAS2B cell line was obtained
from American Type Culture Collection and cultured in
BEGM media with supplements (Lonza, Madrid, Spain)
on collagen-coated culture dishes (10 μg cm-2; rat type I
collagen) at 37°C with 5% CO2 in humidified air. The
culture medium was replaced every 48 hours.
Immunohistochemistry
For immunohistochemical analysis of human pulmonary
tissue from non-smokers, smokers, and smokers with
COPD, tissues were fixed, embedded in paraffin, cut into
sections (4–6 μm), and stained with haematoxylin, as
reported previously [24]. The sections were incubated with
rabbit anti-human TLR3 polyclonal antibody (diluted
1:250; Bioss, Woburn, USA), rabbit anti-human TLR7
polyclonal antibody (1:250; Novus Biologicals®, Madrid,
Spain), rabbit anti-human TLR8 polyclonal antibody
(1:250; Novus Biologicals®, Madrid, Spain) for 24 hours
at 4°C. A secondary anti-rabbit antibody (1:100; Vector
Laboratories, Burlingame, CA) with avidin-biotin com-
plex/horseradish peroxidase (HRP) was used for immu-
nohistochemistry. The non-immune IgG isotype control
was used as negative control. All stained slides werescored by a pathologist under a Nikon Eclipse TE200
(Tokio, Japan) light microscope and representative
photographs taken (10 slices per patient) as previously
outlined [25]. Staining intensity was analyzed in alveo-
lar macrophages and bronchial epithelium of small
bronchi. Staining intensity for TLR3, TLR7, and TLR8
antibodies was scored on a scale of 0–3: 0, negative; 1,
weak; 2, moderate; or 3, strong immunoreactivity. The
percentage of cells positive for TLR3, TLR7 and TLR8
antibodies in alveolar macrophages and within bron-
chial epithelium was scored on a scale of 1–4 as
follows: 1, 0–25% cells positive; 2, 26–50% positive; 3,
51–75% positive; and 4, 76–100% positive. The score
of the staining intensity and the percentage of immu-
noreactive cells were then multiplied to obtain a com-
posite score ranging from 0 to 12.
Western blot
Western blot analyses were performed to detect changes
in TLR3, TLR7, and TLR8 expression in lung tissue from
non-smokers, smokers, and smokers with COPD. The
Bio-Rad assay (Bio-Rad Laboratories Ltd., Herts, UK)
was utilized to quantify the level of protein in each
sample to ensure equal protein loading. Proteins were
separated according to molecular weight by SDS-PAGE.
Briefly, 15 μg of denatured protein and a molecular weight
protein marker (Bio-Rad Kaleidoscope marker; Bio-Rad
Laboratories) were loaded onto an acrylamide gel consist-
ing of a 5% acrylamide stacking gel stacked on a 10%
acrylamide resolving gel and electrophoresed at 100 V for
1 hour. Proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane using a wet blotting method.
The membrane was blocked with 5% Marvel in PBS
containing 0.1% Tween20 (PBS-T), probed with a rabbit
anti-human TLR3 polyclonal antibody (1:1000; Bioss,
Woburn, USA), rabbit anti-human TLR7 polyclonal
antibody (1:1000; Novus Biologicals®, Madrid, Spain),
rabbit anti-human TLR8 polyclonal antibody (1:1000;
Novus Biologicals®, Madrid, Spain), and normalised to
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(1:1000; Sigma). Labeled proteins were detected using
enhanced chemiluminescence methods and reagents (ECL
plus; Amersham GE Healthcare, Buckinghamshire, UK).
Densitometry of films was performed using the Image J
1.42q software (available at http://rsb.info.nih.gov/ij/,
USA) and results are expressed as the ratio of the densi-
tometry of the endogenous control β-actin.
Real Time RT-PCR
Total RNA was isolated from lung parenchyma, primary
HBECs, and BEAS2B bronchial epithelial cells with the
TriPure® Isolation Reagent (Roche, Indianapolis, USA).
The integrity of the extracted RNA was confirmed with
the Bioanalyzer (Agilent, Palo Alto, CA, USA). Reverse
transcription was performed in 300 ng of total RNA
with TaqMan reverse transcription reagents kit (Applied
Biosystems, Perkin-Elmer Corporation, CA, USA). cDNA
was amplified with specific, pre-designed primer sets for
MKP1, MIF, HDAC2, TLR3, TLR7, TLR8, and TRIF and
the housekeeping gene GAPDH (Applied Biosystems) in a
7900HT Fast Real-Time PCR System (Applied Biosystems)
using Universal Master Mix (Applied Biosystems). Relative
quantification of each transcript was determined with
the 2-ΔΔCt method using GAPDH as endogenous control
and normalized to the non-smoker or control groups.
Preparation of cigarette smoke extract solutions
Cigarette smoke extract (CSE) was prepared as previously
outlined [26]. Briefly, the smoke of a research cigarette
(2R4F; Tobacco Health Research, University of Kentucky,
KY, USA) was generated by a respiratory pump (Apparatus
Rodent Respirator 680; Harvard, Germany) through a puff-
ing mechanism similar to the human smoking pattern (3
puffs/min; 1 puff volume of 35 ml; each puff duration last-
ing 2 seconds with 0.5 cm above the filter) and was bubbled
into a flask containing 25 ml of pre-warmed (37°C) Roswell
Park Memorial Institute (RPMI)-1640 culture medium.
The CSE solution was sterilized by filtration through a
0.22 μm cellulose acetate sterilizing system (Corning, USA).
The resulting CSE solution was considered 100% CSE and
was used within 30 minutes of preparation. CSE 10% ap-
proximately corresponds to the exposure associated with
smoking of two packs per day [27]. The quality of the pre-
pared CSE solution was assessed based on the absorbance
at 320 nm, which is the specific light absorption wavelength
of peroxynitrite. Stock solutions with an absorbance value
of 3.0 ± 0.1 were used. To test for cytotoxicity and apoptosis
due to CSE, BEAS2B cells were treated with CSE concen-
trations of up to 5% for 24 hours. No significant differences
in the lactate dehydrogenase supernatant level (lactate de-
hydrogenase cytotoxicity assay; Cayman, Spain) or in the
number of apoptotic cells (annexin V-FITC) were observed
in comparison with the control group [25].Cell stimulations and IL-8 assay
Primary HBECs from non-smoker, smoker, and smokers
with COPD were adjusted to 500 × 103 cells per well in
6-well plates and incubated in BEGM culture medium at
37°C with 5% CO2. Cells were then treated in the pres-
ence or absence of roflumilast N-oxide (0.1 nM-1 μM;
Forest Research Institute, Jersey City, USA), dexametha-
sone (0.1 nM-1 μM; Sigma Aldrich, Madrid, Spain), or
with a combination of fixed concentrations of dexa-
methasone at suboptimal concentrations (10 nM) and
roflumilast N-oxide (1 nM, 10 nM, and 100 nM) for
1 hour. After drug incubations, HBECs were stimulated
with the TLR3 agonist poly I:C at 10 μg/mL or with the
TLR7/8 agonist CL097 (Invivogene, Toulouse, France) at
4 μg/ml final concentration, as previously outlined
[28,29]. Cells were co-incubated with the drugs and the
TLR agonists for 24 hours.
In additional experiments, BEAS2B cells were exposed
to AIR or CSE 1% for 1 hour and then treated for 1 hour
with roflumilast N-oxide (0.1 nM-1 μM), dexamethasone
(0.1 nM-1 μM), or with a combination of fixed concen-
trations of dexamethasone at suboptimal concentration
(10 nM) and roflumilast N-oxide (1 nM, 10 nM, and 100
nM). Cells were then stimulated with poly I:C at 10 μg/
mL or CL097 at 4 μg/ml for 24 hours.
Roflumilast N-oxide and dexamethasone were dis-
solved in dimethyl sulfoxide (DMSO) at 10 mM stock
concentration. Several dilutions of the stocks were per-
formed with cell culture medium. The final concentra-
tions of DMSO (0.1%) in the cell culture did not affect
celular functions. Other chemicals (poly I:C or CL097)
were dissolved in médium.
In other experiments Roflumilast N-oxide was added
at 0, 1 nM, 10 nM or 1 μM. 0 nM corresponds to vehicle
(0.1% DMSO), 2 nM corresponds to the free plasma con-
centrations (unbound to plasma protein) after repeated,
oral, once-daily dosing of roflumilast at the clinical dose
of 500 μg/day [30] and at 1 μM roflumilast N-oxide
completely and selectively inhibits PDE4 [31]. The half-
maximum potency of roflumilast N-oxide to inhibit
PDE4 amounts to 2 nM [31].
Supernatants were collected and centrifuged at 120 g
for 5 minutes. IL-8 was measured in cell-free super-
natant and cellular extracts were utilized to measure
mRNA. IL-8 concentration was determined using a com-
mercially available enzyme-linked immunosorbent assay
kit for IL-8 (R&D Systems, Nottingham, UK).
NF-κB (p65) and AP1 nuclear transcription factor measure
BEAS2B cells were treated with or without CSE 1% for
1 hour and exposed to roflumilast N-oxide (10 nM,
1 μM), dexamethasone (10 nM, 1 μM) or the combin-
ation of roflumilast N-oxide 10 nM plus dexamethasone
10 nM for 1 hour and stimulated with poly I:C 10 μg/mL
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to extract the nuclear protein as previously described [10].
Measurement of nuclear NF-κB (p65) transcription factor
expression was performed using a commercially available
NF-κB (p65) transcription factor assay kit (Cayman Chem-
ical, MI, USA) and with the ELISA AP1 Chemilumines-
cence Kit (Signosis, CA, USA).
Analysis of p38 phosphorylation
BEAS-2B were treated with or without CSE 1% for
1 hour and then exposed to roflumilast N-oxide (10 nM-
1 μM), dexamethasone (10 nM-1 μM), or a combination
for 1 hour. Cells were then stimulated with poly I:C 10
10 μg/mL for 30 minutes. Total protein was extracted
using a lysis buffer consisting of a complete inhibitor
cocktail plus 1 mM ethylenediaminetetraacectic acid
(Roche Diagnostics Ltd, West Sussex, UK) with 20 mM
Tris base, 0.9% NaCl, 0.1% Triton X-100, 1 mM dithio-
threitol and 1 μg/ml pepstatin A. The Bio-Rad assay
(Bio-Rad Laboratories Ltd., Herts, UK) was utilized for
protein quantification to ensure equal protein loading.
To quantify the phosphorylation of p38, Surveyor™ IC
Immunoassay of p38α phosphorylated at T180/Y182 in
cell lysates was employed (R&D Systems Europe, Ltd).
Results were expressed as pg of phosphor-p38/μg of
total protein.
Analysis of results
Statistical analysis of results was carried out by paramet-
ric or non-parametric analysis as appropriate with P <
0.05 considered statistically significant. Non-parametric
tests were used to compare results from the lung tissue
of non-smoker, smoker, and smokers with COPD. In this
case, data were displayed as mean ± standard deviation.
For comparisons between two groups, differences were
analyzed using the Mann–Whitney U test. For compari-
sons between multiple groups, a nonparametric one-way
analysis of variance (Kruskal-Wallis test) was performed
and post hoc comparison were performed using the
Dunn’s post-hoc test, which generalizes the Bonferroni
adjustment procedure. Correlations were analyzed using
the Spearman (ρ) correlation analysis.
In vitro cell experiments were performed in HBECs
from non-smoker, smoker and smokers with COPD and
in BEAS2B cells. Results were expressed as mean ±
standard error of mean (SEM) of n experiments with the
normal distribution for each data set confirmed by histo-
gram analyses and Kolmogorov–Smirnov test. Paramet-
ric analyses were performed and two-group comparisons
were analysed using the two-tailed Student’s paired t-test
for dependent samples or unpaired t-test for independent
samples. Multiple comparisons were analysed by one-way
or two-way analysis of variance followed by Bonferroni
post hoc test.Results
Expression and distribution of TLR3, TLR7 and TLR8 in lung
tissue of non-smokers, smokers and smokers with COPD
TLR3 protein and mRNA expression was upregulated in
lung parenchyma of smokers and smokers with COPD
and inversely correlated with FEV1% in COPD patients
(Figure 1A, B, and C). TLR3 immunostaining was
significantly elevated in alveolar macrophages and
bronchial epithelial cells from smokers and smokers
with COPD compared with non-smokers (Figure 1D,
E, and F). TLR7 expression was detected in nearly all
lung cellular structures, and was similar in lung tissue
from non-smokers, smokers, and smokers with COPD
(Figure 2). In contrast, TLR8 expression was signifi-
cantly downregulated in lung parenchyma of smokers
and smokers with COPD (Figure 3A and B). While
TLR8 showed a marked expression in all lung struc-
tures of non-smokers, the immunohistochemical staining
of TLR8 showed a weak distribution in alveolar macro-
phages and bronchial epithelial cells from smokers and
smokers with COPD (Figure 3C, D, and E).
Anti-inflammatory properties of dexamethasone and
roflumilast N-oxide on primary human bronchial epithelial
cells stimulated with TLR3 agonist
After 24 hours of stimulation with the TLR3 agonist poly
I:C 10 μg/mL, the release of IL-8 was increased in HBECs
from all patients showing higher amounts in cells from
smokers and smokers with COPD. However, the TLR7/8
dual agonist CL097 did not increase IL-8 secretion
(Figure 4A).
In HBECs from non-smoker patients, both roflumilast
N-oxide and dexamethasone inhibited the poly I:C-
induced IL-8 secretion in a concentration-dependent
manner with similar maximal percent inhibition (58.8 ±
1.4% and 59.2 ± 1.2% respectively) and potency (−logIC50
8.28 ± 0.43 roflumilast vs 8.75 ± 0.21 [M] dexametha-
sone; Figure 4B and Table 2). While roflumilast N-oxide
inhibited IL-8 secretion in cells from smokers and
smokers with COPD with similar maximal percent in-
hibition (56.6 ± 2.8% and 50.5 ± 1.5%, respectively) and
potency (−logIC50 8.14 ± 0.21 and 8.28 ± 0.17 [M]), dexa-
methasone showed impaired maximal percent inhibition
in both smokers and smokers with COPD (24.5 ± 7.9%
and 21.6 ± 2.8%, respectively) and impaired potency
in COPD patients (−logIC50 7.84 ± 1.7 [M]; Figure 4C
and D, Table 2).
In HBECs from COPD patients, the combination of sub-
optimal concentrations of dexamethasone (10 nM) with
different concentrations of roflumilast N-oxide (1 nM to
100 nM) additively increased the inhibitory effect of dexa-
methasone on IL-8 release (Figure 4D).
Further study of TLR3 revealed a higher expression
of TLR3 (Figure 5A) and its adaptor TRIF (Figure 6) in
Figure 1 Expression of TLR3 in lung tissues of non-smokers, smokers, and COPD patients. Total protein and mRNA was obtained from
lung tissue of non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15). TLR3 protein and mRNA expression was determined by western blot
(A) and real time PCR (B), respectively, in lung parenchyma. (A) Representative images of western blot for TLR3 and corresponding densitometry
expressed as ratio of β-actin. (B) TLR3 mRNA expression expressed as the ratio to GAPDH. (C) Spearman “ρ” correlation of the protein expression of
TLR3 in COPD patients and lung function, FEV1% predicted. (D, E, F) Lung sections were immunostained for TLR3 and quantified by means of
immunohistochemical score of TLR3 in alveolar macrophages (D) and bronchial epithelial cells (E). (F) Representative immunohistochemistry
images are shown. The control IgG isotype signal was negative. Data are presented as individual values and mean ± standard deviation. Exact
P values were obtained using Kruskal-Wallis and Dunn’s post-hoc tests.
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pared with non-smokers. Interestingly, the TLR3 agonist
poly I:C was able to increase significantly the expression
of TLR3 (Figure 5B, C, and D) and TRIF (Figure 6B, C,
and D) in HBECs from smokers with COPD and to a
lesser extent in smokers and non-smoker subjects. Roflu-
milast N-oxide, reduced the increase of TLR3 and TRIF
induced by poly I:C in all conditions. In contrast, dexa-
methasone only attenuated the increases of TLR3 and
TRIF in non-smokers, but not in smokers or smokers with
COPD (Figures 5 and 6).
Cigarette smoke extract reduces corticosteroid
responsiveness in BEAS2B bronchial epithelial cells
stimulated with TLR3 agonist
In vitro simulation of smoke exposure was assessed to
demonstrate similar behavior of HBECs from smokers
and smokers with COPD and to study the underlying
mechanistic pathways. In this regard, BEAS2B bronchialepithelial cells were incubated with or without cigarette
smoke extract (CSE) 1% for 1 hour, followed by roflumi-
last N-oxide (0.1 nM-1 μM) or dexamethasone (0.1–
1 μM) exposure for 1 hour and the stimulation with poly
I:C 10 μg/mL for additional 24 hours to measure IL-8
supernatant levels. CSE exposed cells showed higher
IL-8 basal release as well as higher IL-8 amounts follow-
ing poly I:C stimulation (Figure 7A). In other experi-
ments, cells with or without exposure to CSE did not
respond to TLR7/8 agonist CL097 (data not shown).
In absence of CSE pretreatment, both roflumilast N-
oxide and dexamethasone concentration-dependently
inhibited IL-8 secretion showing nearly identical max-
imal inhibitory percentage and potency (Figure 7B). In
BEAS2B cells pretreated with CSE, roflumilast N-oxide
inhibited IL-8 release with comparable maximal inhibitory
percentage (44.9 ± 4.7%) and potency (−logIC50 8.08 ± 0.23
[M]; Figure 7C and Table 2) compared with non-exposed
cells. In contrast, inhibition of IL-8 by dexamethasone was
Figure 2 Expression of TLR7 in lung tissues of non-smokers, smokers, and COPD patients. Total protein and mRNA were obtained from
lung tissues of non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15). TLR7 protein and mRNA expression were determined by western
blot (A) and real time PCR (B) in lung parenchyma. (A) Representative images of western blot for TLR7 and corresponding densitometry expressed as
ratio to β-actin. (B) TLR7 mRNA expression given as the ratio to GAPDH. (C, D, E) Lung sections were immunostained for TLR7 and quantified by means
of immunohistochemical score of TLR7 in alveolar macrophages (C) and bronchial epithelial cells (D). (E) Representative immunohistochemistry images
are shown. The control IgG isotype showed negative staining. Data are presented as individual values and mean ± standard deviation. Exact P values
were obtained using Kruskal-Wallis and Dunn’s post-hoc tests.
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inhibitory percentage from 42.6 ± 2.9% to 27.9 ± 6.7%
(Figure 7B and C, Table 2).
Combination of roflumilast N-oxide with dexamethasone
shows additive anti-inflammatory effects: mechanistic
implications
The combination of a fixed non-effective dexamethasone
concentration of 10 nM with different concentrations of
roflumilast N-oxide (1 nM–100 nM) in BEAS2B cells
pretreated with CSE showed additive effects inhibiting
the IL-8 release induced by TLR3 agonist (Figure 7C).
Poly I:C in presence or absence of CSE increased the
expression of TLR3 and its adaptor TRIF in BEAS2B
cells after 24 hours of stimulation (Figure 8A). Roflumi-
last N-oxide and dexamethasone effectively decreased
the poly I:C-induced TLR3 expression in the presence orabsence of CSE. However, in the presence of CSE, only
the combination of roflumilast N-oxide (10 nM) and
dexamethasone (10 nM) inhibited the TRIF overexpres-
sion induced by poly I:C (Figure 8B). IL-8 release induced
by poly I:C in BEAS2B was insensitive to corticosteroids
(Figure 7C). As molecular modulators of corticosteroid
efficacy, we found that HDAC2 gene expression was
downregulated by poly I:C and further decreased in
presence of CSE (Figure 8C). Roflumilast N-oxide at
1 μM partially reversed HDAC2 to control levels, and
the association of roflumilast N-oxide 10 nM and dexa-
methasone 10 nM showed additive effects, increasing
HDAC2 expression (Figure 8C). The expression of MIF
was not modified under any experimental condition
(Figure 8D). The expression of MKP1 was not modified
by poly I:C in the presence or absence of CSE and fol-
lowing roflumilast N-oxide or dexamethasone exposure.
Figure 3 Expression of TLR8 in lung tissues of non-smokers, smokers, and COPD patients. Total protein and mRNA were obtained from
lung tissues of non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15). TLR8 protein and mRNA expression were determined by western
blot (A) and real time PCR (B) in lung parenchyma. (A) Representative images of western blot for TLR8 and corresponding densitometry expressed as
ratio to β-actin. (B) TLR8 mRNA expression given as the ratio to GAPDH. (C, D, E) Lung sections were immunostained for TLR8 and quantified by means
of immunohistochemical score of TLR8 in alveolar macrophages (C) and bronchial epithelial cells (D). (E) Representative immunohistochemistry images
are shown. The control IgG isotype showed negative staining. Data are presented as individual values and mean ± standard deviation. Exact P values
were obtained using Kruskal-Wallis and Dunn’s post-hoc tests.
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nM and dexamethasone 10 nM synergistically increased
MKP1 expression (Figure 8E).
In other experiments, we observed that TLR3 activa-
tion by poly I:C increased the phosphorylation of
mitogen-activated protein kinase p38 as well as the nu-
clear activation of AP-1 and expression of NF-κB (p65)
that were enhanced in the presence of CSE (Figure 9A,
B and C). Roflumilast N-oxide showed inhibitory effects
on phosphorylation of p38 and nuclear activation of
AP-1 and NF-κB in the presence or absence of CSE. In
contrast, dexamethasone showed a poor inhibitory effect
(Figure 8A, B, and C). The combination of roflumilast
N-oxide 10 nM and dexamethasone 10 nM synergistic-
ally inhibited p38, AP-1, and NF-κB which may explain inpart the additive anti-inflammatory effects of roflumilast
N-oxide and dexamethasone in HBECs of COPD patients
following TLR3 activation.
Discussion
The present study provides new evidence on the expres-
sion and distribution profile of the virus innate immune
receptors TLR3, TLR7, and TLR8 in lung tissue of non-
smokers, smokers and COPD patients as well as on the
anti-inflammatory profile of roflumilast N-oxide and re-
duced corticosteroid responsiveness following the activa-
tion of TLR3 in HBECs from current smokers and COPD
patients. Combination of roflimilast N-oxide and dexa-
methasone showed additive anti-inflammatory properties
in HBEC from COPD patients. These results may provide
Figure 4 Roflumilast N-oxide inhibited IL-8 release in human bronchial epithelial cells and demonstrated additive anti-inflammatory
properties in corticosteroid resistance conditions. Human bronchial epithelial cells (HBECs) from non-smokers (n = 4), smokers (n = 4), and
COPD patients (n = 5) were isolated from lung tissues. (A) HBECs from different patients were stimulated with TLR3 agonist poly I:C or the TLR7/8 dual
agonist CL097 for 24 hours and IL-8 levels in the supernatants were measured by ELISA. (B, C, D) HBECs from different patients were incubated with
roflumilast N-oxide (RNO) or dexamethasone (DEX) at different concentrations for 1 hour followed by the stimulation with poly I:C 10 μg/ml for 24 hours
to measure IL-8 release. (D) In COPD patients, fixed concentrations of DEX 10 nM were combined with different RNO concentrations. Results
are expressed as means ± SEM of n= 4–5 (4 non-smoker, 4 smokers, and 5 COPD patients) run in triplicate experiments. Two-way repeated measures
analysis of variance (ANOVA) were performed. Post hoc Bonferroni test: *P< 0.05 compared with solvent controls. #P< 0.05 compared with monotherapy.
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treatment regimen of patients with severe COPD tak-
ing inhaled corticosteroids who still suffer frequent
exacerbations.
Although TLR3 and, to a lesser extent TLR7/8, have
been studied as innate immune viral sensing receptors
promoting inflammatory reactions and anti-viral re-
sponses in different cell types, their distribution and
expression in different lung structures in COPD have
been neglected. Among the few available studies, Todt,
et al. [19] observed that active smoking, (independent
of COPD stage) reduces both the percent of lung mac-
rophages expressing TLR3 and poly I:C-induced CXCL10
production in vitro, without altering other endosomal or
cytoplasmic receptors such as TLR7/8/9, RIG-I, MDA-5
or PKR, so that positive numbers of TLR3-macrophages
directly correlated with lung function. In contrast, Koarai,Table 2 Anti-inflammatory effects of roflumilast N-oxide and
A) HBEC; Non-smokers H
Stimulus Treatment Maximal % inhibition -logIC50 M
Poly (I:C) 10 μg/mL RNO 58.8 ± 1.4 8.28 ± 0.43 56
DEX 59.2 ± 1.2 8.75 ± 0.21 24
B) BEAS2B BE
Treatment Maximal % inhibition -logIC50 M
Poly (I:C) 10 μg/mL RNO 44.5 ± 1.5 8.07 ± 0.15 44
DEX 42.6 ± 2.9 8.06 ± 0.10 27
Inhibition of IL-8 release from (A) human primary bronchial epithelial cells (HBECs) f
disease patients (COPD; n = 5) or (B) BEAS2B cells exposed with or without cigarett
(RNO; 0.1 nM- 1 μM) or Dexamethasone (DEX; 0.1 nM- 1 μM) for 1 hour and stimulate
or without CSE 1% for 1 hour, followed by incubation with RNO or DEX for 1 hour and
independent experiments run in triplicate. IC50 values for half-maximum inhibition wer
non-smoker and smoker group; ┸P < 0.05 vs non-CSE treated group.et al. [17] observed an overexpression of TLR3 in alveolar
macrophages of smokers and COPD patients that in-
versely correlated with lung function. The authors attrib-
uted this discrepancy to methodological differences in
TLR3 determination, design, and endpoints of the experi-
ments testing polyI:C-stimulated mediator production.
Furthermore, a recent work performed by Kinose D, et al.
[32] showed an association of the over-expression of
TLR3 in sputum cells (mainly neutrophils) with the in-
crease of COPD exacerbations which is in line with the
results presented in this work.
To our knowledge, this is the first study which charac-
terizes the main viral pattern recognition receptors
TLR3, TLR7, and TLR8 in different lung structures of
non-smokers, smokers, and COPD patients. TLR3 was
overexpressed in lung parenchyma of current smokers
with and without COPD as assessed by western blot, realdexamethasone in human bronchial epithelial cells
BEC; Smokers HBEC; COPD
aximal % inhibition -logIC50 Maximal % inhibition -logIC50
.6 ± 2.8 8.14 ± 0.21 50.5 ± 1.5 8.28 ± 0.17
.5 ± 7.9* 8.62 ± 0.31 21.6 ± 2.8* 7.84 ± 1.7*#
AS2B + CSE
aximal % inhibition -logIC50
.9 ± 4.7 8.08 ± 0.23
.9 ± 6.7┸ 7.77 ± 0.28┸
rom non-smokers (n = 4), smokers (n = 4) and chronic obstructive pulmonary
e smoke extract (CSE 1%). (A) Cells were incubated with Roflumilast N-oxide
d with Poly (I:C) 10 μg/ml (TLR3 agonist) for 24 hours. (B) Cells were incubated with
stimulated with Poly (I:C) 10 μg/ml for 24 hours. Values are mean ± SEM of 3–5
e calculated by nonlinear regression analysis.*P < 0.05 vs RNO group; #P < 0.05 vs
Figure 5 TLR3 is overexpressed in primary bronchial epithelial cells from current smokers and COPD patients and downregulated by
roflumilast N-oxide. (A) Human bronchial epithelial cells (HBECs) from non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15) were
isolated from lung tissues. (A) mRNA expression of TLR3 in HBECs from different patients was determined by real time PCR as the ratio to GAPDH.
(B, C, D) HBECs from different patients were incubated in the presence or absence of roflumilast N-oxide (RNO) or dexamethasone (DEX) for
1 hour and stimulated with TLR3 agonist poly I:C for 24 hours. Results are expressed as means ± SEM of n = 4–5 (4 non-smokers, 4 smokers, and
5 COPD patients) run in triplicate. Two-way repeated measures analysis of variance (ANOVA) were performed. Post hoc Bonferroni test: *P < 0.05
compared with non-smoker group or with solvent controls. #P < 0.05 compared with poly I:C stimulus.
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Figure 6 TRIF is overexpressed in primary bronchial epithelial cells from current smokers and COPD patients and downregulated by
roflumilast N-oxide. (A) Human bronchial epithelial cells (HBECs) from non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15) were
isolated from lung tissue. (A) mRNA expression of TRIF in HBECs from different patients was determined by real time PCR as the ratio of GAPDH.
(B, C, D) HBECs from different patients were incubated in the presence or absence of roflumilast N-oxide (RNO) or dexamethasone (DEX) for 1 hour and
stimulated with TLR3 agonist poly I:C for 24 hours to measure TRIF mRNA expression. Results are expressed as means ± SEM of n= 3 (3 non-smokers, 3
smokers, and 3 COPD patients) run in triplicate. Two-way repeated measures analysis of variance (ANOVA) were performed. Post hoc Bonferroni
test: *P < 0.05 compared with non-smoker group or with solvent controls. #P < 0.05 compared with poly I:C stimulus.
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Figure 7 BEAS2B bronchial epithelial cells exposed to cigarette smoke and stimulated with TLR3 agonist release IL-8 secretion that is
inhibited by roflumilast N-oxide but not by dexamethasone. BEAS2B cells were pretreated (A, B) without or (A, C) with cigarette smoke
extract (CSE) 1% for 1 h followed by the incubation in the presence or absence of different concentrations of roflumilast N-oxide (RNO) or
dexamethasone (DEX) for 1 h. After drug incubation cells were stimulated with the TLR3 agonist poly I:C for 24 h and IL-8 release was measured by
ELISA. Each graph represents the mean ± SEM of 3–4 independent experiments. One-way repeated measures analysis of variance (ANOVA) were
performed. Post hoc Bonferroni test: *P < 0.05 compared with cells exposed to air; #P < 0.05 compared with monotherapy.
Figure 8 Roflumilast N-oxide regulation of TLR3 expression and molecular pathway implicated in corticosteroid efficacy. BEAS2B cells
were pretreated with or without cigarette smoke extract (CSE) 1% for 1 hour followed by the incubation in the presence or absence of different
concentrations of roflumilast N-oxide (RNO) or dexamethasone (DEX) for 1 hour. After drug incubation cells were stimulated with the TLR3 agonist
poly I:C for 24 hours and total mRNA was extracted to quantify the expression of (A) TLR3, (B) TRIF, (C) HDAC2, (D) MIF, and (E) MKP1 genes by
real time PCR. Each graph represents the mean ± SEM of 3–4 independent experiments. One-way repeated measures analysis of variance (ANOVA) were
performed. Post hoc Bonferroni test: *P < 0.05 compared with control; #P < 0.05 compared with stimulus; ┸P < 0.05 compared with monotherapy.
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Figure 9 Roflumilast N-oxide shows additive or synergistic effects with dexamethasone in inhibiting p38, AP1 and NF-κB induced by
TLR3 stimulation. BEAS2B cells were pretreated with or without cigarette smoke extract (CSE) 1% for 1 hour followed by the incubation in the
presence or absence of different concentrations of roflumilast N-oxide (RNO) or dexamethasone (DEX) for 1 hour. After drug incubation cells were
stimulated with the TLR3 agonist poly I:C for 30 minutes (A), 45 minutes (B), or 1 hour (C), and total protein (A) or nuclear protein (B, C) was
extracted to measure p38 phosphorylation, AP1 nuclear activation, or NF-κB (p65) nuclear expression. Each graph represents the mean ± SEM of
3–4 independent experiments. One-way repeated measures analysis of variance (ANOVA) were performed. Post hoc Bonferroni test: *P < 0.05
compared with control; #P < 0.05 compared with stimulus; ┸P < 0.05 compared with monotherapy.
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versely correlated with lung function in alveolar macro-
phages, as previously reported by Koarai, et al. [17].
TLR3 was also overexpressed in different lung structures
such as alveolar and bronchial epithelium, as well as in
alveolar macrophages of current smokers and COPD pa-
tients. Consequently, the stimulation of HBECs from
smokers and COPD patients with the TLR3 agonist poly
I:C, increased the neutrophilic cytokine IL-8 almost two
folds, supporting the hypothesis for which an elevated
expression of TLR3 in lung tissue from virally exacerbated
COPD patients could mediate inflammatory responses
that overwhelm protective anti-inflammatory defenses,
and thus plays a role in lung chronic inflammation and
remodeling. In fact, a recent study performed in mice
deficient in TLR3/7/9 receptor signaling did not exhibit
cigarette smoke-induced airspace enlargement, which
implicates TLR3 not only in lung inflammation but also in
lung remodeling [33]. TLR3 expression is enhanced by
dsRNA viral exposure aside from the TLR3 stimulation by
its agonist poly I:C and oxidative stress exposure [28,34].
In this work, the TLR3 agonist was able to induce TLR3
and TRIF expression, and cigarette smoke also potentiated
TLR3 and TRIF overexpression in vitro. However, unlike
in non-smokers and smokers, poly I:C increased the TLR3
expression in HBECs from COPD patients by almost 11-
fold, that together with the basal over expression of TRIF
in HBECs from COPD patient suggest a priming HBECs
phenotype which may explain their higher IL-8 release. As
a limitation, we included only patients who were free of
symptoms of upper respiratory bacterial or virus tract
infection. However we cannot discard a chronic subclin-
ical viral bronchial colonization. The presence of non-
symptomatic lung viral colonization could stimulate oralter TLR3 expression representing a limitation of this
study.
In contrast to TLR3, we did not detect differences of
TLR7 expression and distribution in different lung struc-
tures, which is in agreement with the observations made
in alveolar macrophages of non-smokers, smokers, and
COPD patients [19]. However, the expression of TLR8
was decreased in lung parenchyma of smokers and COPD
patients as well as in alveolar macrophages and bronchial
epithelial cells. In contrast to TLR3, the role of TLR7 and
TLR8 in COPD is not well understood. Based in our
in vitro results, the stimulation of TLR7/8 in HBECs from
different patients did not enhance IL-8 secretion. Similar
results in airway epithelial cells have been reported previ-
ously [28,29] suggesting a less prominent role on airway
inflammation for TLR7/8 when compared with TLR3.
The loss of corticosteroid responsiveness is a feature
characteristic of severe asthma and COPD [35]. Further-
more, corticosteroids show impaired anti-inflammatory
properties following airway viral infection as previously
reported [5,6,8,36]. Recent evidence shows that HRV
airway epithelial cell infection impaired dexamethasone-
dependent inhibition of IL-8 release [6]. Additionally, in
an animal asthma model infected with RSV, corticoste-
roids did not reduce lung inflammation [36]. The loss of
corticosteroid responsiveness to lung virus-induced in-
flammation could be mediated by the activation of TLR3
as mice exposed to poly I:C demonstrated a corticoster-
oid resistant airway neutrophilia when treated with or
without cigarette smoke [8].
In this work we observed that HBECs from current
smokers and COPD patients stimulated with TLR3
agonist were insensitive to the anti-inflammatory effects
of dexamethasone. These results were also reproduced
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and stimulated with poly I:C.
Oxidative stress induced by cigarette smoke or chronic
inflammation is known to induce corticosteroid resist-
ance. For example, we and others have shown that
cigarette smoke may induce inflammation resistant to
corticosteroids in different cell types relevant to COPD
such as neutrophils [10], HBECs [37], or alveolar macro-
phages [35]. The increase of oxidative stress generated
by cigarette smoke alters mechanistic pathways related
with corticosteroid activity. It has been shown that
cigarette smoke can phosphorylate mitogen-activated
protein kinases such as p38, JUN or ERK1/2, thus pro-
moting glucocorticoid receptor (GR) hyperphosphoryla-
tion and consequently the inhibition of GR nuclear
translocation [38]. Similar results have been observed in
corticosteroid resistant HRV infected airway epithelial
cells [6]. Other cellular mechanisms that promote cor-
ticosteroid resistance include decreased corticosteroid-
induced mitogen-activated protein kinase phosphatase
1 (MKP1) gene expression, NF-κB over activation, or
HDAC2 downregulation [38]. We have previously dem-
onstrated that neutrophils from COPD patients are in-
sensitive to corticosteroids and deficient in MKP1 and
HDAC2 expression and activity. Furthermore, dexa-
methasone did not inhibit cigarette smoke-induced
NF-κB in neutrophils from COPD patients [10]. In a
similar way, airway epithelial cells infected by HRV im-
paired dexamethasone-induced MKP1 gene expression,
diminished binding of GR to glucocorticoid response
element (GRE), and impaired GR nuclear translocation
as well as NF-κB over activation and GRα hyperpho-
sphorylation [6].
In this work, we observed that HBECs from smokers
and smokers with COPD stimulated with poly I:C in-
creased the TLR3 and TRIF expression which was not
inhibited by dexamethasone. Additionally, the bronchial
epithelial cells exposed to cigarette smoke and stimu-
lated with TLR3 agonist induced HDAC2 downregula-
tion and an increase in p38 phosphorylation and AP1
and NF-κB nuclear expression that were poorly inhibited
by dexamethasone.
PDE4 inhibitors have shown potent anti-inflammatory
properties in several cell types implicated in COPD
pathogenesis (with the exception of alveolar macro-
phages which show a low PDE4 expression [39,40]), and
can decrease the cellular oxidative stress generated by
cigarette smoke and RSV as we previously outlined
[3,9,23]. Additionally, the combination of the PDE4 roflu-
milast with corticosteroids has shown additive or synergis-
tic properties on the activation of anti-inflammatory genes
and the inhibition of proinflammatory cytokines [10,41,42].
In fact, roflumilast increased the GRE signal induced by
corticosteroids in bronchial epithelial cells and increasedexpression of the anti-inflammatory genes induced by GRE
[41]. In neutrophils from COPD patients, roflumilast
showed potent anti-inflammatory properties and the com-
bination of roflumilast with suboptimal dexamethasone
concentrations also increased the anti-inflammatory prop-
erties of dexamethasone. The exploration of the under-
lying mechanisms revealed that roflumilast enhanced the
ability of dexamethasone to increase HDAC2 activity and
MKP1 expression as well as to inhibit ERK1/2 phosphoryl-
ation and NF-κB nuclear expression. In a recent study, we
explored the anti-inflammatory role of roflumilast on the
dsRNA RSV infection and inflammation [9]. Roflumilast
inhibited RSV infection, prevented the loss of cilia and the
secretion of proinflamatory IL-13, IL-6, IL-8, and TNFα,
and decreased formation of ROS. This suggests an anti-
inflammatory role of roflumilast in similar conditions to
those observed in corticosteroid resistance. In the present
work, in contrast to dexamethasone, we observed an in-
hibition of the TLR3 and TRIF expression by roflumilast
N-oxide in HBECs from smokers and smokers with
COPD. Furthermore, roflumilast N-oxide in combin-
ation with dexamethasone showed additive inhibition of
IL-8 release in HBECs from smokers and smokers with
COPD. This association synergistically increased MKP1
and HDAC2 expression in bronchial epithelial cells pre-
treated with cigarette smoke and stimulated with poly I:C.
Similar findings were also observed in neutrophils from
COPD patients that were stimulated with cigarette smoke
[10]. Furthermore, roflumilast N-oxide in combination
with dexamethasone also showed additive inhibitory ef-
fects on p38 phosphorylation and AP1 and NF-κB nuclear
expression.
As previously reported, corticosteroid sensitivity was
restored by inhibiting NF-κB in infected HRV airway
epithelial cells [6] which supports our findings on roflu-
milast N-oxide in cells stimulated with TLR3 agonist.
TLR3 agonist and CSE combination induced resistance
to dexamethasone, however we do not tested whether
the IL-8 increase in BEAS2B due to CSE alone is revers-
ible by roflumilast, dexamethasone or their combination.
In this regard, it has been shown previously that CSE
reduced the increase of GRE nuclear binding induced
by dexamethasone in bronchial epithelial cells, thus
impairing its anti-inflammatory properties [43]. In con-
trast, we previously have observed anti-inflammatory
properties of roflumilast in human bronchial epithelial
cells stimulated with CSE (data not shown). Whether the
combination of roflumilast and dexamethasone reverse cor-
ticosteroid resistance induced by CSE alone, remains to be
explored, although the additive/synergic effects of roflumi-
last and dexamethasone on GRE activation in absence of
oxidative stress has been observed [41] suggesting similar
results under oxidative stress conditions. Besides the utility
of using BEAS2B cell line as a mechanistic model of
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cells could respond differently to stimuli compared to
primary cells, which represents an important limitation
of this study.
Clinically there may be a scientific rationale for using
roflumilast in combination with an inhaled corticosteroid.
In a recent post hoc analysis of two phase III studies,
roflumilast reduced exacerbation frequency in a subgroup
of patients with severe COPD and chronic bronchitis who
were taking an inhaled corticosteroid concomitantly [21].
Moreover, roflumilast is recommended for patients
with severe disease who are already taking a LABA/
inhaled corticosteroid combination. Although not tested
in this work, the triple combination of LABA/inhaled
corticosteroid/roflumilast has shown potent synergistic
anti-inflammatory properties [41]. Frequent exacerbations
of COPD are associated with a high level of inflammation
[44] that may be less sensitive to corticosteroids, thus the
combination of these anti-inflammatory therapies may be
more effective in reducing COPD exacerbations. Anyway,
clinical translation of our findings are far from resolved.
Conclusions
The present work shows that TLR3 expression is up-
regulated in lung tissue from smokers and smokers with
COPD correlating inversely with lung function, while
TLR8 is down-regulated and TLR7 remains unaffected.
TLR3 over-expression triggered IL-8 release in human
bronchial epithelial cells from smokers and smokers with
COPD patients as well as in cells exposed to CSE, that
was insensitive to corticosteroids but not to roflumilast
N-oxide suggesting a prominent role of cigarette smoke
on corticosteroid insensitivity. Combination of roflumi-
last N-oxide with dexamethasone showed additive anti-
inflammatory effects that provide in vitro evidence for
a possible clinical utility to add roflumilast on top of
inhaled corticosteroid in severe COPD.
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